Franklin Genomic Advancements ETF (HELX) Max Pain Analysis
Max pain is the strike price where aggregate option buyer payout is minimized at expiration. It represents the price at which option writers retain the most premium.
Franklin Genomic Advancements ETF (HELX) operates in the Financial Services sector, specifically the Asset Management industry, with a market capitalization near $16.9M, listed on CBOE, carrying a beta of 1.02 to the broader market. The fund seeks capital appreciation by investing in equity securities inside and outside of the United States, including developing or emerging markets. public since 2020-02-27.
Snapshot as of May 15, 2026.
- Spot Price
- $32.94
- Total OI
- 20